In RA models, BAs inhibit NLRP3 inflammasome activation and reduce the release of pro-inflammatory cytokines (such as IL-1β and IL-6) by binding to and activating the TGR5 receptor, thereby triggering the downstream cAMP-PKA signaling pathway (159). Here, IL6 is linked to rheumatoid arthritis.